ATHA vs. AADI, ANEB, FBRX, PLUR, RNTX, ATHE, RNXT, ATRA, PRLD, and XLO
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Aadi Bioscience (AADI), Anebulo Pharmaceuticals (ANEB), Forte Biosciences (FBRX), Pluri (PLUR), Rein Therapeutics (RNTX), Alterity Therapeutics (ATHE), RenovoRx (RNXT), Atara Biotherapeutics (ATRA), Prelude Therapeutics (PRLD), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs.
Athira Pharma (NASDAQ:ATHA) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
Aadi Bioscience has higher revenue and earnings than Athira Pharma. Aadi Bioscience is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aadi Bioscience had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Aadi Bioscience and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Aadi Bioscience's score of -0.47 indicating that Athira Pharma is being referred to more favorably in the media.
Athira Pharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Athira Pharma's return on equity.
Athira Pharma currently has a consensus price target of $13.83, suggesting a potential upside of 5,052.08%. Aadi Bioscience has a consensus price target of $1.67, suggesting a potential downside of 16.25%. Given Athira Pharma's higher possible upside, analysts plainly believe Athira Pharma is more favorable than Aadi Bioscience.
Athira Pharma received 9 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 54.05% of users gave Athira Pharma an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 22.1% of Athira Pharma shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Athira Pharma has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Summary
Athira Pharma beats Aadi Bioscience on 9 of the 15 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ATHA Stock Free ATHA Stock Alerts